Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.59 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.55 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | KCNK3 | O14649 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | KCNK9 | Q9NPC2 | 2/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10031819 | 0.87 | ACHE (0.52) | PARP1HDAC8HDAC6TDP1 | |
| SCHEMBL11065475 | 0.86 | PARP1 (0.57) | PARP1HDAC8HDAC6SMN1; SMN2KCNK3 | |
| SCHEMBL29429340 | 0.86 | PARP1 (0.57) | PARP1HDAC8HDAC6SMN1; SMN2KCNK3 | |
| SCHEMBL16449231 | 0.84 | PARP1 (0.55) | PARP1HDAC8HDAC6SMN1; SMN2KCNK3 | |
| SCHEMBL12164013 | 0.84 | PARP1 (0.60) | PARP1HDAC8HDAC6SMN1; SMN2KCNK3 | |
| SCHEMBL312610 | 0.82 | ACHE (0.62) | PARP1HDAC8HDAC6SMN1; SMN2KCNK3 | |
| SCHEMBL776798 | 0.81 | HDAC8 (0.53) | PARP1HDAC8HDAC6SMN1; SMN2KCNK3 | |
| SCHEMBL29137265 | 0.80 | PARP1 (0.55) | PARP1HDAC8HDAC6SMN1; SMN2KCNK3 | |
| SCHEMBL4434400 | 0.80 | PARP1 (0.55) | PARP1HDAC8HDAC6SMN1; SMN2KCNK3 | |
| SCHEMBL14226767 | 0.80 | DHODH (0.51) | HDAC8POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357302-A1 | TRITERPENE SAPONIN VARIANTS, METHODS OF SYNTHESIS AND USE THEREOF | MEMORIAL SLOAN-KETTERING CANCER CENTER | 2023-11-09 | — | — | US | disclosed |
| US-20230286997-A1 | Compounds for the Treatment of Cancer and Inflammatory Disease | SHY Therapeutics LLC | 2023-09-14 | — | — | US | disclosed |
| US-11731967-B2 | Inhibitors of TRIM33 and methods of use | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-20230149369-A1 | Compounds that Interact with the Ras Superfamily for the Treatment of Cancers, Inflammatory Diseases, Rasopathies, and Fibrotic Disease | SHY Therapeutics LLC (US) | 2023-05-18 | — | — | US | disclosed |
| US-10206893-B2 | Immunoregulatory agents | FLEXUS BIOSCIENCES, INC. (US) | 2019-02-19 | — | — | US | disclosed |
| US-20180111929-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2018-04-26 | — | — | US | disclosed |
| US-20170362201-A1 | COT MODULATORS AND METHODS OF USE THEREOF | GILEAD SCIENCES, INC. | 2017-12-21 | — | — | US | disclosed |
| US-9833455-B2 | Preparation and methods of use for ortho-aryl 5-membered heteroaryl-carboxamide containing multi-targeted kinase inhibitors | SPACEFILL ENTERPRISES LLC (US) | 2017-12-05 | — | — | US | disclosed |
| US-9833455-B2 | Preparation and methods of use for ortho-aryl 5-membered heteroaryl-carboxamide containing multi-targeted kinase inhibitors | SPACEFILL ENTERPRISES LLC (US) | 2017-12-05 | — | — | US | disclosed |
| US-9815818-B2 | Cot modulators and methods of use thereof | GILEAD SCIENCES, INC. (US) | 2017-11-14 | — | — | US | disclosed |
| US-20110015239-A1 | INHIBITORS OF CALCIUM-ACTIVATED CHLORIDE CHANNELS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-01-20 | — | — | US | disclosed |
| US-20110015239-A1 | INHIBITORS OF CALCIUM-ACTIVATED CHLORIDE CHANNELS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-01-20 | — | — | US | disclosed |
| US-7863288-B2 | protein kinase modulators such as Propane-1-sulfonic acid [2,4-difluoro-3-(5-ethoxy-1H-pyrrolo[1,3-b]pyridine-3-carbonyl)-phenyl]-amide, used to regulate signal transduction cascades, involved in the control of physiological functions including cellular growth and proliferation; anticarcinogenic agents | PLEXXIKON, INC. (US) | 2011-01-04 | — | — | US | disclosed |
| US-20100228026-A1 | NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-09-09 | — | — | US | disclosed |
| US-7645771-B2 | CCR5 antagonists as therapeutic agents | SMITHKLINE BEECHAM CORP. (US) | 2010-01-12 | — | — | US | disclosed |
| US-20090280106-A1 | Pituitary adenylate cyclase acivating peptide (pacap) receptor (vpac2) agonists and their pharmacological methods of use | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-11-12 | — | — | US | disclosed |
| US-7504391-B2 | Selective D1/D5 receptor antagonists for the treatment of obesity and CNS disorders | SCHERING CORPORATION (US) | 2009-03-17 | — | — | US | disclosed |
| US-20080274304-A1 | Functionalized Photoreactive Compounds | ROLIC AG (CH) | 2008-11-06 | — | — | US | disclosed |
| US-20080146564-A1 | 1,3-Dihydro-Benzimidazol-2-Ylidene Amines as Inhibitors of Respiratory Syncytial Virus Replication | JANSSEN SCIENCES IRELAND UC (IE) | 2008-06-19 | — | — | US | disclosed |
| US-20070213375-A1 | Triazole derivatives useful as Axl inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2007-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170362201-A1 | COT MODULATORS AND METHODS OF USE THEREOF | BRDT, THRB, HCCS | PARP1 1381/4885HDAC8 1199/4885HDAC6 1192/4885 |
| US-11731967-B2 | Inhibitors of TRIM33 and methods of use | TRIM33, TRIM28, TRIM4 | PARP1 342/4885HDAC8 747/4885HDAC6 673/4885 |
| US-10206893-B2 | Immunoregulatory agents | IDO1, IDO2, INMT | PARP1 2823/4885HDAC8 785/4885HDAC6 331/4885 |
| US-20080146564-A1 | 1,3-Dihydro-Benzimidazol-2-Ylidene Amines as Inhibitors of Respiratory Syncytial Virus Replication | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CBR1, RTF2 | PARP1 2050/4885HDAC8 3870/4885HDAC6 2956/4885 |
| US-20080274304-A1 | Functionalized Photoreactive Compounds | PCNA, PIN1, MAP1LC3C | PARP1 43/4885HDAC8 4749/4885HDAC6 1394/4885 |
| US-20090280106-A1 | Pituitary adenylate cyclase acivating peptide (pacap) receptor (vpac2) agonists and their pharmacological methods of use | ADCYAP1R1, VIPR2, ADCY2 | PARP1 2034/4885HDAC8 911/4885HDAC6 930/4885 |
| US-20230286997-A1 | Compounds for the Treatment of Cancer and Inflammatory Disease | MAPK6, MAP3K6, MAPK4 | PARP1 2112/4885HDAC8 556/4885HDAC6 553/4885 |
| US-20180111929-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | PARP1 1237/4885HDAC8 536/4885HDAC6 719/4885 |
| US-20230357302-A1 | TRITERPENE SAPONIN VARIANTS, METHODS OF SYNTHESIS AND USE THEREOF | LSS, GALE, CYP4A11 | PARP1 3976/4885HDAC8 1292/4885HDAC6 4035/4885 |
| US-20230149369-A1 | Compounds that Interact with the Ras Superfamily for the Treatment of Cancers, Inflammatory Diseases, Rasopathies, and Fibrotic Disease | HRAS, KRAS, NRAS | PARP1 3841/4885HDAC8 2133/4885HDAC6 1627/4885 |
| US-20070213375-A1 | Triazole derivatives useful as Axl inhibitors | AXL, TYRO3, FLT3 | PARP1 3367/4885HDAC8 535/4885HDAC6 959/4885 |
| US-20100228026-A1 | NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | REN, AGTR2, AGTR1 | PARP1 4745/4885HDAC8 1059/4885HDAC6 1499/4885 |
| US-20110015239-A1 | INHIBITORS OF CALCIUM-ACTIVATED CHLORIDE CHANNELS | CLCN2, CLIC1, CLIC4 | PARP1 4868/4885HDAC8 4432/4885HDAC6 2298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.